With all of the hoopla on Capitol Hill over Valeant Pharmaceuticals International Inc.'s aggressive pricing practices involving drugs like Isuprel (isoprenaline) and Nitropress (sodium nitroprusside) – whose prices were hiked considerably after the company acquired the medicines from Marathon Pharmaceuticals in February – it was inevitable it wouldn't take long until federal prosecutors got involved.
And they did.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?